Complete American Beacon Stephens Small Cap Growth Fund;R5 funds overview by Barron's. View the STSIX funds market news ...
Chicago Marathon announced that it has extended its partnership with Nike through 2036, continuing a relationship that began ...
A novel molecule plus rituximab was associated with higher response rates vs. rituximab alone, according to study data ...
UBS Global Biopharma Conference 2026 November 16, 2026 6:20 AM EST Hello. All right. Thank you, everyone, for coming today. My name is Dejia Zhang, and I'm on the UBS Investment Banking coverage team.
Everest Medicines raised HK$1.57B via a 2025 share placement, but its stock fell 63% by 2026 despite 142% revenue growth and ...
Travere Therapeutics has achieved two significant FDA approvals for FILSPARI, driving notable revenue growth. See why I rate ...
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...
Detailed price information for Addus Homecare Corp (ADUS-Q) from The Globe and Mail including charting and trades.
DENVER — Sefaxersen, a novel messenger RNA-targeted therapy was linked to greater reduction in proteinuria and more likely resolution of baseline hematuria vs. placebo for patients with immunoglobulin ...
Travere Therapeutics (NASDAQ: TVTX) is attempting to change the pattern via which rare kidney diseases are treated. The ...
Investor's Business Daily on MSN
Travere crashed into its 200-day line and then reversed higher; here's why
Shares of Travere Therapeutics took a hit Tuesday, but closed in the green, after fewer than expected patients started taking its drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results